Going all in: Biogen commits an extra $500M to Alzheimer’s blockbuster hopeful aducanumab
Biogen CEO Michel Vounatsos is going all in on his late-stage Alzheimer’s drug aducanumab.
The big biotech said today that it paid Neurimmune, which out-licensed the drug to Biogen, $150 million to cut its negotiated royalty rate for post-approval sales by 15%. And it’s prepared to pay another $50 million for another 5% rate reduction.
The $200 million deal comes on top of yesterday’s announced plan to restructure Biogen’s partnership with Eisai on aducanumab, which one prominent analyst expects will cost Biogen about $300 million in added research costs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
